China Shineway Pharmaceutical Group Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
China Shineway Pharmaceutical Group şirketinin toplam hissedar öz sermayesi CN¥7.3B ve toplam borcu CN¥330.0M olup, bu da borç-öz sermaye oranını 4.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥9.9B ve CN¥2.5B dir. China Shineway Pharmaceutical Group 'in FAVÖK'ü CN¥944.7M faiz karşılama oranı -5.7 dur. Şirketin CN¥6.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
4.5%
Borç/özkaynak oranı
CN¥330.00m
Borç
| Faiz karşılama oranı | -5.7x |
| Nakit | CN¥6.23b |
| Eşitlik | CN¥7.34b |
| Toplam yükümlülükler | CN¥2.55b |
| Toplam varlıklar | CN¥9.88b |
Son finansal sağlık güncellemeleri
Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13
China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10
Recent updates
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Oct 18If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity
Jun 03Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461
Apr 26Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?
Apr 17China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461
Mar 31China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings
Mar 14Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?
Jan 29China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118
Sep 01We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Aug 03Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?
May 30We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Mar 07China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125
Sep 01China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 31China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.
Mar 11Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?
Feb 18Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?
Jan 31Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?
Jan 13What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?
Dec 25We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years
Nov 25Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 2877 'nin kısa vadeli varlıkları ( CN¥8.5B ) kısa vadeli yükümlülüklerini ( CN¥2.4B ) aşıyor.
Uzun Vadeli Yükümlülükler: 2877 şirketinin kısa vadeli varlıkları ( CN¥8.5B ) uzun vadeli yükümlülüklerini ( CN¥113.0M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 2877 şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: 2877 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 4.5% seviyesine yükseldi.
Borç Kapsamı: 2877 'nin borcu işletme nakit akışı ( 356.2% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: 2877 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.